-
Product Insights
Hypersomnia - Drugs In Development, 2024
Empower your strategies with our Hypersomnia – Drugs In Development, 2024 report and make more profitable business decisions. Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes (such as seasonal affective disorder) and can cause distress and problems with functioning. It is a pathological state characterized by a lack of alertness during the waking episodes of the day. The main symptom of hypersomnia is excessive daytime sleepiness (EDS), or prolonged nighttime...
-
Product Insights
MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) - Drugs In Development, 2024
Empower your strategies with our MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2024 report and make more profitable business decisions. Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is one of the family of mitochondrial diseases. A feature of this diseases is that it is caused by defects in the mitochondrial genome which is inherited purely from the female parent. The most common MELAS mutation is mitochondrial mutation, mtDNA, referred to as m.3243A>G. Symptoms typically...
-
Product Insights
Vascular Dementias - Drugs In Development, 2024
Empower your strategies with our Vascular Dementias – Drugs In Development, 2024 report and make more profitable business decisions. Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. Vascular dementia can be caused by ischemic or hemorrhagic infarcts affecting multiple brain areas, including the anterior cerebral artery territory, the parietal lobes, or...
-
Product Insights
Chronic Traumatic Encephalopathy (CTE) - Drugs In Development, 2024
Empower your strategies with our Chronic Traumatic Encephalopathy (CTE) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease linked to repeated trauma to the head. It causes the death of nerve cells in the brain, known as degeneration. First-stage symptoms are confusion, disorientation, dizziness, and headaches. Second-stage symptoms include memory loss, social instability, impulsive behavior, and poor judgment. Third and fourth stages include progressive dementia, movement disorders, hypomimia, speech impediments,...
-
Product Insights
Dystonia - Drugs In Development, 2024
Empower your strategies with our Dystonia – Drugs In Development, 2024 report and make more profitable business decisions. Dystonia is a neurological hyperkinetic movement disorder in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures. Dystonia is often intensified or exacerbated by physical activity, and symptoms may progress into adjacent muscles The Dystonia drugs in development market research report provide comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage...
-
Product Insights
Globoid Cell Leukodystrophy (Krabbe Disease) - Drugs In Development, 2024
Empower your strategies with our Globoid Cell Leukodystrophy (Krabbe Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Krabbe disease, also called globoid cell leukodystrophy, is a degenerative disorder caused by a deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, muscle spasms, loss of head control, vomiting, fever, irritability, and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsants, muscle relaxers) and...
-
Product Insights
Guillain-Barre Syndrome - Drugs In Development, 2024
Empower your strategies with our Guillain-Barre Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot...
-
Product Insights
Encephalitis - Drugs In Development, 2024
Empower your strategies with our Encephalitis – Drugs In Development, 2024 report and make more profitable business decisions. Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune system....
-
Product Insights
Infantile Spasm (West Syndrome) - Drugs In Development, 2024
Empower your strategies with our Infantile Spasm (West Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Infantile Spasm also known as West Syndrome is a type of seizures and most seen in children. Observed in children up to 5 years of age and can develop into other seizures in rare cases. Sudden stiffening of arms and legs, head thrown back, commonly observed when woke up from sleep and rare in sleep. These seizures last for four...
-
Product Insights
Status Epilepticus - Drugs In Development, 2024
Empower your strategies with our Status Epilepticus – Drugs In Development, 2024 report and make more profitable business decisions. Status epilepticus is an emergency neurological condition where seizures last for more than five minutes; historically, it was diagnosed for seizures longer than than 30 minutes. Patients with this condition do not regain consciousness between seizures, which can lead to death. Hence, it requires immediate emergency evaluation and management. Seizures can be convulsive or non-convulsive, and are most commonly observed in pediatric...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.